Comparing DT Cloud Star Acquisition (NASDAQ:DTSQ) & Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO) and DT Cloud Star Acquisition (NASDAQ:DTSQ) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, valuation and institutional ownership.

Profitability

This table compares Agios Pharmaceuticals and DT Cloud Star Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%
DT Cloud Star Acquisition	N/A	N/A	N/A

Valuation and Earnings

This table compares Agios Pharmaceuticals and DT Cloud Star Acquisition”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03 million	36.70	-$412.78 million	($7.01)	-4.74
DT Cloud Star Acquisition	N/A	N/A	N/A	N/A	N/A

DT Cloud Star Acquisition has lower revenue, but higher earnings than Agios Pharmaceuticals.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Agios Pharmaceuticals and DT Cloud Star Acquisition, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1	4	5	0	2.40
DT Cloud Star Acquisition	0	1	0	0	2.00

Agios Pharmaceuticals presently has a consensus target price of $41.25, suggesting a potential upside of 24.19%. Given Agios Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts plainly believe Agios Pharmaceuticals is more favorable than DT Cloud Star Acquisition.

Risk & Volatility

Agios Pharmaceuticals has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, DT Cloud Star Acquisition has a beta of -0.01, meaning that its share price is 101% less volatile than the S&P 500.

Summary

Agios Pharmaceuticals beats DT Cloud Star Acquisition on 5 of the 8 factors compared between the two stocks.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

About DT Cloud Star Acquisition

DT Cloud Star Acquisition Corporation focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2022 and is based in Brooklyn, New York.